Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees

Published

on

Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

A little-noticed policy shift by the Trump administration caused a seven-year delay in choosing a costly AbbVie medicine for Medicare price negotiations, a move likely to hurt taxpayers, according to an analysis by a consumer advocacy group.

The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices that the agency would pay for a limited number of medicines. The process was created by the Inflation Reduction Act, which became law in 2022 in response to the rising cost of prescription drugs.

Continue to STAT+ to read the full story…

Read More

Published

on

A little-noticed policy shift by the Trump administration caused a seven-year delay in choosing a costly AbbVie medicine for Medicare price negotiations, a move likely to hurt taxpayers, according to an analysis by a consumer advocacy group.

The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices that the agency would pay for a limited number of medicines. The process was created by the Inflation Reduction Act, which became law in 2022 in response to the rising cost of prescription drugs.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

BioVie shares halve on murky Parkinson’s disease readout

BioVie shares halve on murky Parkinson’s disease readout

Published

on

BioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the one submitted to the FDA.​ ​Read More

Continue Reading

Uncategorized

Takeda approval ushers in new wave of sleep drugs

An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.

Read More

Published

on

An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.

Read More

Continue Reading
Advertisement

Trending